| 2.19 -0.37 (-14.45%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.49 |
1-year : | 4.08 |
| Resists | First : | 2.99 |
Second : | 3.5 |
| Pivot price | 2.73 |
|||
| Supports | First : | 2.18 |
Second : | 1.81 |
| MAs | MA(5) : | 2.57 |
MA(20) : | 2.82 |
| MA(100) : | 3.86 |
MA(250) : | 3.43  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8 |
D(3) : | 14 |
| RSI | RSI(14): 30.8 |
|||
| 52-week | High : | 7.13 | Low : | 1.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GALT ] has closed below the lower bollinger band by 17.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ GALT ] is to continue within current trading range. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.55 - 2.57 | 2.57 - 2.59 |
| Low: | 2.14 - 2.16 | 2.16 - 2.18 |
| Close: | 2.16 - 2.19 | 2.19 - 2.21 |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Sun, 05 Apr 2026
Galectin Therapeutics (GALT) Eps Diluted (TTM) - Zacks Investment Research
Fri, 03 Apr 2026
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Fri, 03 Apr 2026
HC Wainwright Boosts FY2026 Earnings Estimate for Galectin Therapeutics - National Today
Fri, 03 Apr 2026
FY2026 Earnings Estimate for GALT Issued By HC Wainwright - marketbeat.com
Thu, 02 Apr 2026
Galectin Therapeutics (GALT) Receives Buy Rating: How Will This Impact the Shares? - Bitget
Thu, 02 Apr 2026
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 29.8 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 6,570 (K) |
| Shares Short P.Month | 5,090 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -3.72 |
| PEG Ratio | 0 |
| Price to Book value | -1.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|